Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26958140 | 0.97 | MAPT (0.38) | OPRM1OPRD1OPRK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL26958143 | 0.94 | OPRM1 (0.38) | OPRM1OPRD1OPRK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL26941574 | 0.88 | OPRM1 (0.35) | OPRM1OPRD1OPRK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL24397743 | 0.86 | DRD2 (0.39) | SMN1; SMN2ALDH1A1MAPTDRD3HSD11B1 | |
| SCHEMBL24398057 | 0.86 | MAPK1 (0.36) | OPRM1OPRD1OPRK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL26941609 | 0.86 | ALDH1A1 (0.37) | OPRM1OPRD1OPRK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL26941586 | 0.85 | OPRM1 (0.35) | OPRM1OPRD1OPRK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL24397839 | 0.84 | MAPT (0.38) | OPRM1OPRD1OPRK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL24397915 | 0.84 | OPRM1 (0.33) | OPRM1OPRD1OPRK1DRD3 | |
| SCHEMBL26941636 | 0.84 | MAPT (0.39) | OPRM1OPRD1OPRK1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399287-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| US-20230399289-A1 | ITACONIC ACID DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399287-A1 | NOVEL COMPOUNDS | CNKSR1, RORC, HLA-DRB1 | OPRM1 4344/4885OPRD1 3272/4885OPRK1 3019/4885 |
| US-20230399289-A1 | ITACONIC ACID DERIVATIVES | IL1R1, LRBA, HCAR1 | OPRM1 4873/4885OPRD1 4738/4885OPRK1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.